Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer

被引：0
|
作者：
Keun-Wook Lee
Yu Jung Kim
Kyung-Hun Lee
Sae-Won Han
Tae-Yong Kim
Do-Youn Oh
Seock-Ah Im
Tae-You Kim
Yung-Jue Bang
In Sil Choi
Jee Hyun Kim
机构：
[1] Seoul National University College of Medicine,Department of Internal Medicine, Seoul National University Bundang Hospital
[2] Seoul National University College of Medicine,Department of Internal Medicine, Seoul National University Hospital
[3] Seoul National University College of Medicine,Department of Internal Medicine, SMG
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Metastatic colorectal cancer; Chemotherapy; Refractory; Gemcitabine; UFT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：447 / 455
页数：8
相关论文
共 50 条
  • [31] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [32] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [33] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [34] ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’
    J Bennouna
    H Perrier
    B Paillot
    F Priou
    J H Jacob
    M Hebbar
    S Bordenave
    J F Seitz
    F Cvitkovic
    E Dorval
    K Malek
    D Tonelli
    J Y Douillard
    British Journal of Cancer, 2006, 94 : 69 - 73
  • [35] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [36] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    E Vasile
    G Masi
    L Fornaro
    S Cupini
    F Loupakis
    S Bursi
    I Petrini
    S Di Donato
    I M Brunetti
    S Ricci
    A Antonuzzo
    S Chiara
    D Amoroso
    M Andreuccetti
    A Falcone
    British Journal of Cancer, 2009, 100 : 1720 - 1724
  • [37] Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients
    Koji Okabayashi
    Hirotoshi Hasegawa
    Yoshiyuki Ishii
    Takashi Endo
    Hiroki Ochiai
    Tetsuro Kubota
    Yuko Kitagawa
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 501 - 507
  • [38] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [39] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
    J-P Delord
    J Bennouna
    P Artru
    H Perrier
    F Husseini
    F Desseigne
    E François
    R Faroux
    D Smith
    P Piedbois
    H Naman
    J Y Douillard
    R Bugat
    British Journal of Cancer, 2007, 97 : 297 - 301
  • [40] Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
    Siemerink, Ester J. M.
    Drenth, Annemieke F. J.
    Mulder, Nanno H.
    Plukker, John T. M.
    Hospers, Geke A. P.
    GASTRIC CANCER, 2010, 13 (02) : 95 - 100
12345